Printer Friendly

CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE IMPLANTS OF LIVING CELLS TO TREAT CHRONIC PAIN

 CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE
 IMPLANTS OF LIVING CELLS TO TREAT CHRONIC PAIN
 MINNEAPOLIS, April 28 /PRNewswire/ -- The Neurological Division of Medtronic, Inc. (NYSE: MDT) and CytoTherapeutics, Inc. (NASDAQ: CTTI), announced today that they have concluded a research agreement to pursue the use of encapsulated living cells for the treatment of chronic pain.
 The core technology of CytoTherapeutics consists of proprietary techniques for encapsulation of cells of tissue within semi-permeable polymer membranes. These colonies of living cells can then be inserted into the body where they receive nutrients and produce desired therapeutic proteins. This technology may allow therapeutic use of substances secreted by cells that offer advantages over traditional and biotechnology-derived medicines.
 Medtronic has taken an equity position in the company and will support research by its collaborators at Brown University, the University of Illinois, and at Rush Presbyterian Medical Center, Chicago, Ill. Further financial terms were not disclosed.
 Initial investigation will involve delivery of encapsulated cells that secrete pain-disrupting neurotransmitters inside the spinal sheath via a specialized catheter. The project will seek methods of controlling pain from diseases such as cancer by disrupting transmission of pain signals via the spinal cord to the brain.
 CytoTherapeutics, Inc., of Providence, R.I., was formed in 1989 to develop cellular therapies based on membrane encapsulation technologies acquired from Brown and Washington Universities. The company's two leading product candidates, NeuroCRIB(TM) and EndoCRIB(TM), are intended to treat Parkinson's disease and diabetes, respectively.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 4/28/92
 /CONTACT: Erika Karplus of CytoTherapeutics, 401-272-3310, ext. 136; Dale Beumer (Investor Relations), 612-574-3038 or Dick Reid (Public Relations), 612-574-3052; or Peter Feinstein of Feinstein Partners, 617-577-8110/
 (MDT CTTI) CO: Medtronic, Inc.; CytoTherapeutics, Inc. ST: Minnesota IN: MTC SU: JVN


KH -- MN006 -- 3638 04/28/92 09:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:312
Previous Article:PERSONAL DIAGNOSTICS REPORTS NET INCOME OF $622,000 ($.13 PER SHARE) IN SECOND FISCAL QUARTER
Next Article:HOGAN SYSTEMS REPORTS FOURTH-QUARTER AND YEAR-END RESULTS FOR FY92


Related Articles
CYTOTHERAPEUTICS AND MEDTRONIC TO INVESTIGATE IMPLANTS OF LIVING CELLS TO TREAT CHRONIC PAIN
CYTOTHERAPEUTICS REPORTS FIRST QUARTER RESULTS
CYTOTHERAPEUTICS NAMES E. EDWARD BAETGE DIRECTOR OF NEUROSCIENCE
CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
CYTOTHERAPEUTICS ANNOUNCES BROAD U.S. PATENT COVERING THE USE OF MULTIPLE CELL TYPES IN THERAPEUTIC IMPLANTS
CYTOTHERAPEUTICS ANNOUNCES FIRST QUARTER 1993 RESULTS
CYTOTHERAPEUTICS REPORTS PRELIMINARY RESULTS OF CERECRIB IMPLANT TRIAL FOR CHRONIC CANCER PAIN
CYTOTHERAPEUTICS AND MEMBRANA JOIN FORCES TO DEVELOP NEW MEMBRANES FOR ENCAPSULATED CELL THERAPY
CYTOTHERAPEUTICFS INITIATES U.S. PHASE I CLINICAL TRIAL OF PRODUCT TO TREAT CHRONIC PAIN IN CANCER PATIENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters